Roswell Park Cancer Institute has started a new, unique clinical trial investigating immunotherapy for patients with advanced ovarian cancer. Dr. Emese Zsiros, the study's Principal Investigator, explains the hope behind combining pembrolizumab (Keytruda) with intravenous bevacizumab (Avastin) and oral cyclophosphamide (Cytoxan). Read more: [ Ссылка ]
